



Product Specifications


Custom Oligo Synthesis, antisense oligos, RNA oligos, chimeric oligos, Fluorescent dyes, Affinity Ligands, Spacers & Linkers, Duplex Stabilizers, Minor bases, labeled oligos, Molecular Beacons, siRNA, phosphonates Locked Nucleic Acids (LNA); 2'-5' linked Oligos

Oligo Modifications

For research use only. Not for use in diagnostic procedures for clinical purposes.

Locked Analog T

Category	Duplex Stability
Modification Code	+T
Reference Catalog Number	26-6520
5 Prime	Y
3 Prime	Y
Internal	Y
Molecular Weight(mw)	332.2



LNA is a bicyclic nucleic acid where a ribonucleoside is linked between the 2'-oxygen and the 4'-carbon atoms with a methylene unit. Locked Nucleic Acid (LNA) was first described by Wengel and co-workers in 1998 (8-10) as a novel class of conformationally restricted oligonucleotide analogues. The design and ability of oligos containing locked nucleic acids (LNAs) to bind supercoiled, double-stranded plasmid DNA in a sequence-specific manner has been described by Hertoghs et al (6) for the first time. The main mechanism for LNA oligos binding plasmid DNA is demonstrated to be by strand displacement. LNA oligos are more stably bound to plasmid DNA than similar peptide nucleic acid (PNA) 'clamps' for procedures such as particle mediated DNA delivery (gene gun). It is shown that LNA oligos remain associated with plasmid DNA after cationic lipid-mediated transfection into mammalian cells. LNA oligos can bind to DNA in a sequence-specific manner so that binding does not interfere with plasmid conformation or gene expression (6). LNA Oligonucleotides exhibit unprecedented thermal stabilities towards complementary DNA and RNA, which allow excellent mismatch discrimination (8). The high binding affinity of LNA oligos allows for the use of short probes in antisense protocols and LNA is recommended for use in any hybridization assay that requires high specificity and/or reproducibility, e.g., dual labeled probes, in situ hybridization probes, molecular beacons and PCR primers. Furthermore, LNA offers the possibility to adjust T_m values of primers and probes in multiplex assays. Each LNA base addition in an oligo increases the T_m by approximately 80C. As a result of these significant characteristics, the use of LNA-modified oligos in antisense drug development is now coming under investigation, and recently the therapeutic potential of LNA has been reviewed (11). The synthesis and incorporation of LNA bases can be achieved by using standard DNA synthesis chemistry. Detailed research results have not yet concluded as to the amount of LNA bases and regular DNA base combination in successful antisense and gene delivery experiments. The investigator can elect to substitute individual bases in the oligo to LNA bases or use a combination. Due to the high affinity and thermal stability of the LNA: DNA duplex it is not advised to have more than 15 LNA bases in an oligo; this induces strong self-hybridization. The use of LNA C base requires special synthesis and post synthesis protocols.

LNA-containing oligonucleotides can be purified and analyzed using the same methods employed for standard DNA. LNA can be mixed with DNA and RNA, as well as other nucleic acid analogues, modifiers and labels. LNA oligonucleotides are water soluble, and can be separated by gel electrophoresis and precipitated by ethanol. *License Agreement: Locked-nucleic Acid (LNA) phosphoramidites are protected by EP Pat No. 1013661, US Pat No. 6,268,490 and foreign applications and patents owned by Exiqon A/S. Products are made and sold under a license from Exiqon A/S. Products are for research purposes only. Products may not be used for diagnostic, clinical, commercial or other use, including use in humans. There is no implied license for commercial use, including contract research, with respect to the products and a license must be obtained directly from Exiqon A/S for such use.